[Effect of trastuzumab for human esophageal cancer].
The effects on esophageal cancer of monoclonal antibody trastuzumab, directed against the HER2 protein, were evaluated in this study. Immunohistochemical study showed that 90% (45/50) of esophageal cancer specimens expressed HER2 protein, and flow cytometric analysis showed that 4 kinds of human esophageal cancer cells (TT, TE2, TE6, TE10) expressed high levels of HER2 protein. Trastuzumab treatment (100-500 ng/ml) was not able to inhibit the growth of the all kinds of cancer cells, but the combination treatment of trastuzumab and peripheral mononuclear cells resulted in antibody dependent cell-mediated cytotoxicity (ADCC) against the cancer cells TE6 and TE10 in a dose dependent manner. Intraperitoneal injection of trastuzumab at 1 mg/body twice a week for 5 weeks significantly inhibited the growth of mice-bearing xenografts of TE6 and TE10. Our results suggest that trastuzumab therapy is useful in the treatment of human esophageal cancer.
Yamazaki
Masanao
M
Dept. of Surgical Oncology, Osaka City University Graduate School of Medicine.
Yamashita
Yoshito
Y
Kubo
Naoshi
N
Ohira
Masaichi
M
Hirakawa
Kosei
K
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized; D000920:Antibody-Dependent Cell Cytotoxicity; D000970:Antineoplastic Agents / Q000494:pharmacology*; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab